Compare PRZO & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRZO | LPCN |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 19.1M |
| IPO Year | 2022 | 2011 |
| Metric | PRZO | LPCN |
|---|---|---|
| Price | $0.56 | $2.36 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 531.9K | 187.9K |
| Earning Date | 03-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $92.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $1.81 |
| 52 Week High | $2.15 | $12.37 |
| Indicator | PRZO | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 31.26 | 34.39 |
| Support Level | N/A | $2.20 |
| Resistance Level | $0.82 | $2.50 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 17.29 | 52.02 |
ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.